Clinical Trial

Trial of THEO-260 in Ovarian Cancer Patients

Study acronym: OCTOPOD
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-04-15
notable Enrollment increased: 28 -> 44 participants 2026-04-15
notable Primary completion pushed: 2027-07 -> 2028-06 2026-04-15
minor Completion pushed: 2027-07 -> 2028-06 2026-04-15
Trial Details
NCT Number NCT06618235
Lead Sponsor Theolytics Limited
Conditions Ovarian Cancer
Enrollment 44 participants
Start Date 2024-09-24
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-14